Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.

Autor: Xiao, Bingkun, Wang, Weilan, Zhang, Dezhi
Zdroj: OncoTargets & Therapy. Aug2018, Vol. 11, p5059-5074. 16p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje